700 million people are affected by mental illness, addiction or eating disorders. And mushrooms can help.

Not the kind you might find at a Grateful Dead concert but the medicinal mushroom molecule of psilocybin.

Doug Drysdale is the CEO of Cybin, a biotechnology company working to advance psychedelic pharmaceutical treatments for mental health issues and addiction.

On this episode of The Wiggin Sessions, Doug joins me to discuss the research around treating major depression with psilocybin and explain how his team is making classical psychedelics more accessible.

Doug describes the size of the market for treating depression, addiction and eating disorders, differentiating Cybin’s work from the psychedelic microdosing trending in Silicon Valley.

Listen in for Doug’s insight on the differences between medicinal marijuana and psilocybin—and learn how investing in Cybin looks to be a win-win for stockholders and anyone living with mental illness.

Key Takeaways Cybin’s work to make classical psychedelic drugs both faster and shorter acting

How Cybin is making psychedelic treatments for depression, addiction and anxiety more accessible

The findings of the Johns Hopkins study on treating major depression with psilocybin

How psilocybin works to make patients more receptive to psychotherapy

Cybin’s innovation in delivering psychedelic therapies (direct contact with bloodstream vs. oral delivery)

The enormous size of the market for treating addiction, depression and eating disorders

Why Cybin is building out an entire care model that includes a psychotherapy program

The differences between medicinal marijuana and psychedelic therapeutics

Why developing psychedelic microdosing treatments is much more challenging than Cybin’s macrodosing treatments

When Cybin’s stock was listed on the NYSE and how that affected the team’s work

How volatility in stock price impacts a biotech company’s ability to finance testing

The potential for consolidation in the biotech space over the next few years

Connect with Doug Drysdale Cybin

Connect with Addison Wiggin Consilience Financial

Be sure to follow The Wiggin Sessions on your socials. You can find me on—

Facebook @thewigginsessions

Instagram @thewigginsessions

Twitter @WigginSessions

Resources Psilocybin Research

‘Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder’ in JAMA Psychiatry

Cybin’s EMBARK Program

Greenbrook TMS

Cybin’s Collaboration with Greenbrook TMS

GW Pharmaceuticals